SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-142944
Filing Date
2022-05-06
Accepted
2022-05-06 07:00:33
Documents
12
Period of Report
2022-05-05
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d296710d8k.htm   iXBRL 8-K 39118
  Complete submission text file 0001193125-22-142944.txt   161511

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nrix-20220505.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20220505_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20220505_pre.xml EX-101.PRE 11262
6 EXTRACTED XBRL INSTANCE DOCUMENT d296710d8k_htm.xml XML 3356
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 22898790
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences